Last reviewed · How we verify
Regimen：BIC+FTC+TAF
Regimen：BIC+FTC+TAF is a Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by National Center for AIDS/STD Control and Prevention, China CDC. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).
This combination regimen inhibits HIV reverse transcriptase and integrase to suppress viral replication and prevent AIDS progression.
The regimen BIC+FTC+TAF is used to treat HIV infection. BIC, FTC, and TAF are small molecule drugs that work together to combat HIV.
At a glance
| Generic name | Regimen：BIC+FTC+TAF |
|---|---|
| Sponsor | National Center for AIDS/STD Control and Prevention, China CDC |
| Drug class | Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Bictegravir (BIC) is an integrase strand transfer inhibitor that blocks HIV integration into host DNA. Emtricitabine (FTC) and tenofovir alafenamide (TAF) are nucleoside/nucleotide reverse transcriptase inhibitors that prevent viral RNA-to-DNA conversion. Together, these three agents target different steps of the HIV replication cycle to achieve potent viral suppression.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (weight-based dosing)
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Elevated creatinine
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regimen：BIC+FTC+TAF CI brief — competitive landscape report
- Regimen：BIC+FTC+TAF updates RSS · CI watch RSS
- National Center for AIDS/STD Control and Prevention, China CDC portfolio CI
Frequently asked questions about Regimen：BIC+FTC+TAF
What is Regimen：BIC+FTC+TAF?
How does Regimen：BIC+FTC+TAF work?
What is Regimen：BIC+FTC+TAF used for?
Who makes Regimen：BIC+FTC+TAF?
What drug class is Regimen：BIC+FTC+TAF in?
What development phase is Regimen：BIC+FTC+TAF in?
What are the side effects of Regimen：BIC+FTC+TAF?
What does Regimen：BIC+FTC+TAF target?
Related
- Drug class: All Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV integrase, HIV reverse transcriptase
- Manufacturer: National Center for AIDS/STD Control and Prevention, China CDC — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Indication: Drugs for HIV-1 infection in adolescents and children (weight-based dosing)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing